BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new preclinical data showing that treatment with PEG-SN38, Enzon’s PEGylated SN38 compound, resulted in excellent antitumor activity in xenograft models of non-Hodgkin’s lymphoma (NHL). The data were presented at the ASH (American Society of Hematology) Conference in Atlanta, Georgia.
